Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1a/1b study of LY4170156 in folate receptor alpha-expressing advanced solid tumors
jRCT2031240270Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 1, open-label trial of sofetabart mipitecan in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC) and 7 more (6 arms), sponsored by Eli Lilly and Company. Primary endpoints: Recommended phase 2 dose based on dose-limiting toxicities, Recommended phase 2 dose or optimal dose based on dose-limiting toxicities and 1 more. Started Aug 2024; status: recruiting.
02
Drugs
sofetabart mipitecan
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)endometrial cancer (EC)Cervical Cancer (CC)
Beyond the preview
Go deeper on jRCT2031240270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240270.